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and events attributed to OIC including the negative impact on job-related activi-
ties. Methods: A prospective longitudinal study conducted in the United States 
(US), Canada (CN), UK (UK), and Germany (GE) of patients with OIC who have been 
on opioid therapy for at least four weeks was conducted. OIC related medical history 
and health care resource use was collected from participants self report. The num-
ber of hours missed from work and the extent to which the work productivity and 
regular daily activities were affected was collected using the WPAI-SHP. Results: 
A total of 489 eligible participants (US: 238; CN: 38;, GE: 115; UK: 98). Back pain 
(77%) and joint pain (52%) were the most common pain diagnosis with an average 
duration of chronic pain and opioid medication use of 10 and 6 years respectively. 
27% of participants were currently employed. 18% of participants used at least 
one prescription laxative; 70% reported using at least one over-the-counter (OTC) 
laxative with the most common being stimulant laxatives (20%), osmotic laxatives 
(15%) and stool softeners (7%). 63% of participants reported discussing OIC with a 
health care provider, 3.0% reported a visit to the emergency room and 2.0% reported 
being admitted to a hospital because of their OIC during a 6-month time period. 
9% of employed participants reported missing an average of 4.6 hours per week 
because of problems associated with constipation and 32% reported impairment 
while working due to constipation. ConClusions: The cumulative impact of OTC 
use, physician office visits and the negative impact on work-related activities for 
OIC may be substantial.
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objeCtives: Neuroblastoma (NB) is a rare cancer of childhood, with nearly 90% of 
cases diagnosed by age 5 (ACS 2013). Our objective was to report the utilisation and 
cost of hospital services related to patients who have a diagnosis of NB and High 
Risk NB (HRNB) reported in an England dataset from a Clinical Commissioning 
Group (CCG) perspective. Methods: We used an England dataset covering hospi-
tal events (April 2010 - September 2013). Patients were included if they were under 
age 18 and had a hospital event with a primary or secondary diagnosis coded as 
International Classification of Disease 10thEdition (ICD10) C749. Newly diagnosed 
patients were identified if they had no hospital events in the first 4 months of 
the study period. From this newly diagnosed cohort we identified a HRNB cohort 
(bone marrow transplant) that included patients who had a high risk procedure 
that did not occur in the last 12 months of the study period. Cost and utilisation is 
reported from hospital admissions, emergency department visits, and outpatient 
attendances. Results: We observed 336 patients as newly diagnosed and an addi-
tional 33 patients were identified as HRNB. Newly diagnosed population inpatient 
admits were 12 per patient, compared with 22 per patient for the HRNB population. 
Total costs associated with the 336 newly diagnosed patients were £24.3m. Total 
costs associated with the 33 HRNB patients were £4.3m. Costs per HRNB patient 
(£130,303) were almost double the costs per newly diagnosed patient (£72,321). 
The average length of stay was 6 days for both sets of patients. ConClusions: 
To our knowledge this is the first retrospective analysis of NB cost and utilisation 
using encounter data from England. While it does not capture the entire costs to 
the England health care system, it indicates the level of resource intensity and 
cost at the CCG level.
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objeCtives: Patients’ profile undergoing intravenous immunobiological treatment 
is very limited. This study aimed to describe this information from the perspective of 
a Brazilian health plan, located in Fortaleza. Methods: This was a cross sectional 
study with data obtained from the HMO database as presented by Reis H et al at 
ISPOR 18th Annual Meeting. Eligible criteria for data analysis were patients being 
treated for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis 
(PsA) or Crohn’s disease (CD) who have received at least one dose of immunobiologi-
cal drug between March/2012 and October/2013. Data was stratified by indication 
(RA, AS, PsA and CD), patient weight and treatment profile (naïve versus non-naïve 
patients). Results: A total of 118 patients had been analyzed, with an average 
age of 51 years, and 66.9% (n = 79) of them being women. RA (n = 53,44,9%) and AS 
(n = 49,41,5%) were the most prevalent diseases being treated, followed by PsA 
(n = 13,11%) and CD (n = 3,2, 5%). The average weight of patients varied according 
to the disease being treated: 67 kg for RA and CD, and 70 kg for AS and PsA. It was 
observed that 65.5% patients were naïve to immunobiological drug, of which 73% 
initiated treatment with an anti-TNFa, being infliximab the most commonly pre-
scribed one (85.2%). As for patients who had already been previously treated, goli-
mumab and abatacept were the most commonly prescribed drugs (23%), whereas 
48.7% out of total were receiving the third immunobiogical drug and 35.9% were 
receiving the second one. ConClusions: The knowledge of patients profile and 
treatment information is the basis for any planning strategy in an HMO. Associated 
with costs, this data is crucial in supporting HMO board decisions on best treatment 
alternatives and so optimize the provided care.
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bursement status and availability of top 20 orphan drugs in Slovakia from 2005 
till 2012. Data were obtained from government sources. Results: We considered 
orphan drugs list (Cote and Keating, 2012) that exceeded 1 billion $ sales in 2008 
(globally) and compared molecules’ availability in Slovakia. Same molecules are 
among best selling 20 orphan drugs in Slovakia, with highest sale of 95 million EUR 
(Bevacizumab, 2005-2012) compared to lowest sale of 19 million EUR (Tacrolimus, 
2005-2012). It took from 1 (Imatinib) to 19 years (Glatiramer acetate) to be launched 
in Slovakia after orphan designation. Top 20 orphan drugs had average DOT 472 
EUR compared to total pharma market DOT average 0,43 EUR. From selected orphan 
drugs 60% had full (100%) reimbursement status and 40% were fully covered by 
hospital budgets. Only 4 of them were launched in Slovakia since 2005 (included), 16 
of them were launched from 1990 till 2004. Prices ranged from 330 EUR to 5800 EUR 
(ex-factory, one package, 2012). ConClusions: There are highly valuable incentives 
for industry to invest in to development of orphan drugs in EU. Current context of 
economic constraints in EU however justifies the need to pay close attention to the 
rationale of maintaining such incentives in the context of potential return on invest-
ments of companies offering high priced drugs. Top 20 orphan drugs in Slovakia 
have prices high above average and also full reimbursement status. We expect more 
restrictive drug policy measures in this field.
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objeCtives: In 2006 the American College of Medical Genetics (ACMG) developed 
a stakeholder survey to make recommendations for 84 rare conditions to be con-
sidered for mandatory newborn screening (NBS). Scores of 19 different surveyed 
attributes for each condition were totaled. These scores determined an entry point 
to an algorithm (EPA) that determined final recommendations (Core conditions, 
Secondary Targets or Not Recommended). Among these attributes was a contro-
versial one - non-patient benefits (NPB). Such attributes have historically not been 
considered in mandatory screening recommendations. This analysis examines 
how the exclusion of this attribute would affect recommendations. Methods: 
The ACMG report provided scores for individual attribute survey responses. We 
deleted the attribute score for NPB (0 to 100 points) and rescored the totals for 
each condition. We then assessed whether score changes were sufficient to alter 
the EPA and whether a different EPA would result in changes to the recommenda-
tions. Results: Six conditions had missing data. Of the 78 remaining, there were 
15 conditions (19%) whose initial total scores were capable of changing by enough 
in this exercise (maximum 100 point reduction) to change the EPA. Of those, 10 (67%) 
did change EPA and, of those, 3 (30%) changed final category (in all cases from Core 
to ST). Of the initial 29 recommended Core conditions, there would be a 10 percent 
reduction to 26 and an increase in Secondary Targets from 25 to 28. ConClusions: 
Including screening benefits to non-patients (family or society) is controversial 
and has not been standard in the past. We have shown that in the ACMG recom-
mendations, had no changes been made to the algorithm consequent to dropping 
non-patient benefits from consideration, 3 conditions would have changed from a 
Core recommendation for screening to only a Secondary Target.
PSY110
aCCeSS to orPHan drUgS in greeCe dUring eConomiC CriSiS
Tsiantou V.1, Mylona K.1, Karampli E.1, Boubouchairopoulou N.1, Kyriopoulos I.I.1, 
Athanasakis K.1, Gabriel E.2, Makridaki D.3, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Institute of Pharmaceutical Research and 
Technology, Pallini, Greece, 3Panhellenic Association of Hospital Pharmacists, Marousi, Greece
objeCtives: Orphan Drugs (ODs) are medicinal products intended for diagnosis, 
prevention or treatment of rare diseases. Access to ODs is crucial for patients’ health 
and quality of life. The aim of this study was to identify current problems and future 
challenges of patients’ access to ODs in Greece. Methods: A qualitative study took 
place between December 2013 and January 2014. Data were retrieved through semi-
structured interviews with six representatives of key stakeholders in Greece and 
policy documents identified through web searches using keywords “orphan drugs” 
and “rare diseases” in Greek. Web-based documents and transcribed interviews were 
content analyzed. Results: Delays in pricing and reimbursement of ODs in the 
Greek pharmaceutical market, budget cuts in hospitals and absence of patient reg-
istries constitute according to the analysis the greatest barriers in patients’ access 
to ODs. There are two main channels through which the patient can have access 
to an OD and it depends whether it is licensed in Greece or not. In the first case 
the patient can take the drug through the hospital or the pharmacy of EOPYY if it 
is not available at the hospital pharmacy and in the second case through a public 
sector organization (IFET). All cases are characterized by extensive bureaucracy and 
involvement of up to three organizations in order to receive the approval, a proce-
dure creating delays in patients’ access and risking their health. Also, the absence of 
a well-described procedure and lack of cooperation between the organizations and 
committees create further delays. ConClusions: Ensuring patients’ access to ODs 
in Greece is challenging especially during the economic crisis. Financial constraints 
and continuous legislative changes in the health system and the pharmaceutical 
market constitute important barriers to patients’ access. There is a need to describe, 
organize and communicate the pathway of patients’ access to ODs.
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objeCtives: To describe the health care resource utilization associated with the 
diagnosis, treatment, and general management of opioid-induced constipation (OIC) 
